Forgot Password?
Return to Course Listing

CME: Ovarian Cancer: Therapeutic Updates, Best Practices, and Emerging Treatments

Activity Description / Statement of Need:

In this online, self-learning activity:

In the U.S., there are over 22,000 new cases of ovarian cancer and close to 14,000 related deaths per year. ~ 90% of malignant ovarian tumors are epithelial carcinomas (serous, endometrioid, mucinous, clear cell, transitional cell, and squamous) while the remainder are non-epithelial (germ cell, sex cord/stromal tumors). Risk factors for ovarian cancer includes: early menarche and late menopause, nulliparity, family history of breast cancer or ovarian cancer, and BRCA1 or -2 mutations; whereas factors associated with a protective effective include: oral contraceptives, breastfeeding, and tubal ligation, among others.

Described as a neoplastic “silent killer” for its nonspecific symptomology and the likelihood that it will not present until disease has progressed, the 5-year survival rate in ovarian cancer drops precipitously from better than 90% when the disease is localized to between 10% and 30% once it has advanced. The initial workup of the pelvic mass includes abdominal imaging with assessment of other symptoms including bloating, early satiety and/or loss of appetite, pelvic or abdominal pain, increased urinary urgency and frequency, irritable bowel syndrome, unexplained weight loss/fatigue/changes in bowel habits, and ascites as clinically warranted.

Target Audience:

HCPs specializing in: medical oncologists and oncology surgeons; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and other clinicians who commonly encounter patients with ovarian cancer or those who might benefit from screening.


Commercial Support Disclosure: This program is supported by an educational grant from Merck.

This activity is free of charge.


Release Date: April 16, 2020 -- Expiration Date: April 16, 2022

Faculty: June Hou, MD

Agenda

Faculty introduction, disclosures

Introduction content: cursory refresher and review

  • Epidemiology: statistics by severity
  • Causes and risk factors
  • Clinical features, presentation, histopathology, BRCA status
  • Pathogenesis, DNA damage response
  • Diagnosis and present controversies in screening practices
  • Staging, comorbidities, and complications

Treatment strategies in ovarian cancer

How has the treatment landscape changed in the last decade, and where is it going?

  • Mechanisms of action and impact on biochemical pathways and the cell life cycle
  • Recurrent disease: platinum-sensitive vs. not
  • Emerging therapies and their mechanisms, including targeted: VEGF, PARP, BRCA mutated, PD-1, wee1 kinase, TSP-1, HIF-1a, HDAC-4, tumor treating fields
  • Safety profiles of current and emerging agents
  • Updates in the recent clinical literature
  • Clinical pearls in current practice: the ongoing relationship between healthcare professional and patient – education and other barriers to care
  • Best practice: putting it all together
  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Identify patients who may benefit from screening of ovarian cancer and discuss current clinical controversies around screen practices.
  • Describe present treatment strategies for ovarian cancer, weighing their risk-benefit profiles in the setting of patient cases, and identify emerging treatment, discussing their potential or anticipated place(s) in therapy.
  • Recognize the appropriate therapeutic choices in individual patients with ovarian cancer based on their demographic and clinical characteristics, applying them to patient cases.
  • Describe the importance of the role of the healthcare professional as educator in the treatment of patients with ovarian, and brainstorm other ways in which the provider might help the patient overcome other barriers in care.

Accreditation

This activity has been planned and implemented in accordance with the accreditation standards and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physicians: Please note: not all activities on this site provide MOC credit. If this activity does not specify that it provides MOC credit in the "Accreditation" section on this page, then it does NOT provide MOC credit.

Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education.Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-20-015-H01-P.  ACPE Accreditation effective 4/25/2020, expires 4/25/2022.

This is a Knowledge (K)-type activity.

Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.  ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: June Y. Hou, MD, Assistant Professor of Gynocologic Oncology, Columbia University, Ervings Medical Center, New York, has received financial compensation as a consultant for Foundation Medicine, Inc., Massive Bio, Inc., and Immunogen Inc.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Commercial Support Disclosure: This program is supported by an educational grant from Merck.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Recurrent and metastatic endometrial cancer: Therapeutic updates and optimizing treatment

Advanced prostate cancer: Optimizing management strategies

Advances in Treating Triple-Negative Metastatic Breast Cancer: Optimizing Pharmacotherapeutic Management Strategies